1. Academic Validation
  2. Structure-Property Investigation of New "KetoFAPI" Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential

Structure-Property Investigation of New "KetoFAPI" Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential

  • J Med Chem. 2025 Oct 23;68(20):21739-21765. doi: 10.1021/acs.jmedchem.5c02102.
Pawel Brzeminski 1 Emile Verhulst 2 Adrian Fabisiak 1 Roberta Pacifico 1 Daan Willocx 3 Sarah Peeters 1 Anke de Groot 2 Sam Corthaut 2 Kim Van Meel 2 Sigrid Stroobants 3 Koen Augustyns 1 Maya Berg 4 Anne-Marie Lambeir 2 4 Frank Rösch 5 Ingrid De Meester 2 4 Filipe Elvas 3 Pieter Van der Veken 1 4
Affiliations

Affiliations

  • 1 Laboratory of Medicinal Chemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Antwerp 2610, Belgium.
  • 2 Laboratory of Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Antwerp 2610, Belgium.
  • 3 Molecular Imaging and Radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp 2610, Belgium.
  • 4 Infla-Med Centre of Excellence, University of Antwerp, Antwerp 2610 , Belgium.
  • 5 Institut für Kernchemie, Johannes Gutenberg University of Mainz, Fritz-Strassman-Weg 2, Mainz D-55128, Germany.
Abstract

Fibroblast activation protein α (FAP) is a serine protease that has emerged as an attractive, pan-cancer radiotheranostic target. The development of effective FAP-targeting radiotheranostics critically relies on the identification of FAP inhibitors that achieve prolonged tumor retention, thereby maximizing therapeutic efficacy and ensuring sustained tumor irradiation, regardless of radionuclide half-life considerations. Here, we present the design, synthesis, and biological evaluation of potent and selective FAP inhibitors bearing an electrophilic α-ketoamide warhead (ketoFAPIs). Through structure-activity relationship studies, we identified highly potent compounds with selectivity over prolyl oligopeptidase (PREP) by up to 3 orders of magnitude. Moreover, this manuscript shows for the first time that ketoFAPIs can exhibit significantly longer target residence times than first-generation FAPIs comprising an electrophilic carbonitrile warhead, which in turn translates into extended tumor retention in a mouse Cancer model. This work lays the groundwork for the use of ketoFAPIs as a versatile platform for the development of FAP-targeted radiopharmaceuticals.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-178981
    FAP Inhibitor
    FAP